ALXO ALX Oncology Holdings

ALX Oncology to Participate in Upcoming Investor Conferences in September

ALX Oncology to Participate in Upcoming Investor Conferences in September

SOUTH SAN FRANCISCO, Calif., Aug. 29, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives, today announced that ALX Oncology leadership will participate in both the Cantor Global Healthcare Conference 2025 and H.C. Wainwright 27th Annual Global Investment Conference in New York.

The details of the meetings are as follows:

Cantor Global Healthcare Conference

Format: Fireside Chat and One-on-one Meetings

Date: Wednesday, September 3, 2025

Location: New York, NY

Time of Fireside Chat Presentation: 9:45 AM ET

Webcast link: Available

H.C. Wainwright 27th Annual Global Investment Conference

Format: One-on-one meetings

Date: Tuesday, September 9, 2025

Location: New York, NY

Webcast link: Pre-recorded fireside chat presentation available

The webcasts of the Cantor and H.C. Wainwright fireside chats can be accessed by visiting the Investors section of ALX Oncology’s website at under the section of the Events and Presentations tab. Replays of the webcasts will be archived for up to 90 days following the fireside chat dates.

About ALX Oncology

ALX Oncology (Nasdaq: ALXO) is a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives. ALX Oncology’s lead therapeutic candidate, evorpacept, has demonstrated potential to serve as a cornerstone therapy upon which the future of immuno-oncology can be built. Evorpacept is currently being evaluated across multiple ongoing clinical trials in a wide range of cancer indications. ALX Oncology’s second pipeline candidate, ALX2004, is a novel EGFR-targeted antibody-drug conjugate with a differentiated mechanism of action and entered the clinic in a Phase 1 trial in August 2025. More information is available at  and on LinkedIn .

Investor Relations Contact:

Elhan Webb, CFA, IR Consultant

Media Contact:

Audra Friis, Sam Brown Healthcare Communications

(917) 519-9577



EN
29/08/2025

Underlying

ALXOALX Oncology Holdings

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ALX Oncology Holdings

Jonathan Moreland
  • Jonathan Moreland
Free Trial
WSBC WESBANCO INC.
WOR Worthington Ind... ... (+47)

InsiderInsights Weekly Report: September 27, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

WSBC WESBANCO INC.
WOR WORTHINGTON INDUSTRIES INC.
NMFC NEW MOUNTAIN FINANCE CORPORATION
NGL NGL ENERGY PARTNERS LP
MTDR MATADOR RESOURCES COMPANY
FRPT FRESHPET INC
FCN FTI CONSULTING INC.
CDNA CAREDX INC
BUSE FIRST BUSEY CORPORATION
KRNY KEARNY FINANCIAL CORP.
NEXT NEXT BIOMETRICS GROUP ASA
CULP CULP INC.
PBHC PATHFINDER BANCORP INC.
ESP ESPEY MANUFACTURING & ELECTRONICS CORP.
BHB BAR HARBOR BANKSHARES
HAIN THE HAIN CELESTIAL GROUP
MBIN INC.
AROC MERCHANTS BANCORP
ARVN ARCHROCK INC.
BCDA ARVINAS HOLDING
UUU BIOCARDIA
SAVA UNIVERSAL SECURITY INSTRUMENTS INC.
COO CASSAVA SCIENCES
AOUT THE COOPER COMPANIES INC.
ALXO AMERICAN OUTDOOR BRANDS
AMR INC.
OPEN ALX ONCOLOGY HOLDINGS
SMMT ALPHA METALLURGICAL RESOURCES INC
PFBX OPENDOOR TECHNOLOGIES INC.
ABSI SUMMIT THERAPEUTICS INC
RYAN PEOPLES FINANCIAL CORP. (MISSISSIPPI)
MRVL ABSCI CORP
KMPH RYAN SPECIALTY GROUP HLDGS INC
BUKS MARVEL BIOSCIENCES CORP
OBLG KEMPHARM INC
VANI BUTLER NATIONAL CORP
SMRT OBLONG INC
PRAX VIVANI MEDICAL INC
NBBK SMARTRENT INC
NCDL PRAXIS PRECISION MEDICINES INC
BHRB NB BANCORP INC.
CAMP NUVEEN CHURCHILL DIRECT LENDING CORP
SI BURKE HERBERT FINANCIAL SERVICES CORP
JSPR CAMP4 THERAPEUTICS CORPORATION
BDSX SHOULDER INNOVATIONS INC
AMPLITUDE HEALTHCARE ACQUISITION CORP
BIODESIX INC
09/29/25 September 29, 2025 1 EN
Jonathan Moreland
  • Jonathan Moreland
Free Trial
WSBC WESBANCO INC.
SNPS SYNOPSYS INC. ... (+33)

InsiderInsights Weekly Report: September 20, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

WSBC WESBANCO INC.
SNPS SYNOPSYS INC.
NMFC NEW MOUNTAIN FINANCE CORPORATION
NGL NGL ENERGY PARTNERS LP
MTDR MATADOR RESOURCES COMPANY
FRPT FRESHPET INC
BUSE FIRST BUSEY CORPORATION
ASA ASA
CELC CELCUITY
MBIN MERCHANTS BANCORP
AROC ARCHROCK INC.
CCEL CRYO-CELL INTERNATIONAL
GRX THE GABELLI HEALTHCARE & WELLNESSRX TRUST
ALXO ALX ONCOLOGY HOLDINGS
DLHC DALEIGH HOLDINGS CORP
AMR ALPHA METALLURGICAL RESOURCES INC
OPEN OPENDOOR TECHNOLOGIES INC.
CTO CONSOLIDATED-TOMOKA LAND CO
PFBX PEOPLES FINANCIAL CORP. (MISSISSIPPI)
NEXT NEXT CAPITAL
RYAN RYAN SPECIALTY GROUP HLDGS INC
KMPH KEMPHARM INC
BUKS BUTLER NATIONAL CORP
OBLG OBLONG INC
VANI VIVANI MEDICAL INC
RH RESTORATION HARDWARE HOLDINGS INC
SMRT SMARTRENT INC
NBBK NB BANCORP INC.
NCDL NUVEEN CHURCHILL DIRECT LENDING CORP
BHRB BURKE HERBERT FINANCIAL SERVICES CORP
CAMP CAMP4 THERAPEUTICS CORPORATION
SI SHOULDER INNOVATIONS INC
MSTR MICROSTRATEGY INCORPORATED
09/21/25 September 21, 2025 1 EN
Jonathan Moreland
  • Jonathan Moreland
Free Trial
WSBC WESBANCO INC.
NMFC New Mountain Fi... ... (+10)

InsiderInsights.com Daily Ratings Report: September 18, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

WSBC WESBANCO INC.
NMFC NEW MOUNTAIN FINANCE CORPORATION
LPSN LIVEPERSON INC.
FRPT FRESHPET INC
NEXT NEXTDECADE
MBIN MERCHANTS BANCORP
CCEL CRYO-CELL INTERNATIONAL
ALXO ALX ONCOLOGY HOLDINGS
PFBX PEOPLES FINANCIAL CORP. (MISSISSIPPI)
RH RESTORATION HARDWARE HOLDINGS INC
09/19/25 September 19, 2025 1 EN
 PRESS RELEASE
Free
ALXO ALX Oncology Ho...

ALX Oncology Appoints Board Member Barbara Klencke, M.D., as Interim C...

ALX Oncology Appoints Board Member Barbara Klencke, M.D., as Interim Chief Medical Officer Dr. Barbara Klencke is an accomplished clinical leader with a distinguished track record in oncology drug development who currently serves on the Company’s Board of Directors and will step down from the Board to join ALX as Interim Chief Medical Officer Alan Sandler, M.D. resigns as Chief Medical Officer and will return to his position serving on the Company’s Board of Directors SOUTH SAN FRANCISCO, Calif., Sept. 12, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or “the Comp...

September 12, 2025 1 EN
 PRESS RELEASE
Free
ALXO ALX Oncology Ho...

ALX Oncology to Participate in Upcoming Investor Conferences in Septem...

ALX Oncology to Participate in Upcoming Investor Conferences in September SOUTH SAN FRANCISCO, Calif., Aug. 29, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives, today announced that ALX Oncology leadership will participate in both the Cantor Global Healthcare Conference 2025 and H.C. Wainwright 27th Annual Global Investment Conference in New York. The details of the meetings are as follows: Cantor Global...

August 29, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch